EswatiniTuberculosis profile
Population  2017 1.4 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.14 (0.09–0.21) 10 (6.6–15)
Mortality (HIV+TB only) 0.6 (0.43–0.81) 44 (31–59)
Incidence  (includes HIV+TB) 4.2 (3.2–5.3) 308 (236–389)
Incidence (HIV+TB only) 2.9 (1.9–4.2) 213 (138–304)
Incidence (MDR/RR-TB)** 0.42 (0.28–0.58) 31 (20–43)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.37 (0.35–0.4) 1.5 (1.2–1.7) 1.8 (1.5–2.1)
Males 0.42 (0.39–0.45) 2 (1.6–2.3) 2.4 (1.9–2.8)
Total 0.79 (0.71–0.88) 3.4 (2.6–4.2) 4.2 (3.2–5.3)
TB case notifications, 2017  
Total cases notified 3 544
Total new and relapse 3 367
          - % tested with rapid diagnostics at time of diagnosis 86%
          - % with known HIV status 94%
          - % pulmonary 87%
          - % bacteriologically confirmed among pulmonary 74%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.18 (0.12–0.25)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 2 191 69%
          - on antiretroviral therapy 2 060 94%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  240
(200–290)
Estimated % of TB cases with MDR/RR-TB 6.8% (5.4–8.4) 16% (11–21)  
% notified tested for rifampicin resistance 66% 75% 2 363
MDR/RR-TB cases tested for resistance to second-line drugs   172
Laboratory-confirmed cases MDR/RR-TB: 203, XDR-TB: 4
Patients started on treatment **** MDR/RR-TB: 208, XDR-TB: 10
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 83% 3 403
Previously treated cases, excluding relapse, registered in 2016 76% 196
HIV-positive TB cases registered in 2016 83% 2 369
MDR/RR-TB cases started on second-line treatment in 2015 68% 305
XDR-TB cases started on second-line treatment in 2015 75% 8
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment <1%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
7.4% (6.8–8.2)
TB financing, 2018  
National TB budget (US$ millions) 12
Funding source: 14% domestic, 86% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-26 Data: www.who.int/tb/data